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o The Opioid epidemic is a very prevalent issue and intravenous 
drug use is one of the leading causes of infective endocarditis 
(IE) today 
o IE and the course of the disease in IV drug users tends to 
differ from other patients 
o IV Drug Users: right heart, tricuspid valve, more likely to also have 
pneumonia, younger, less likely to need surgery 
o Non-IV Drug Users: left heart, aortic and mitral valve, more likely to 
also have history of CVA and/or PVD, older, more indications for 
surgery
Retrospective review of 1,302 records of 
LVHN patients diagnosed with IE 
Narrowed down to 75 patients who 
underwent cardiac valve surgery for 
endocarditis from October 2015 – June 2019  
Patient data was organized into two groups: 
IV drug users and non-IV drug users  
The results were compared; postoperative 
mortality and total hospital charges were the 
primary outcome focuses.       
o Analyze the demographics, medical histories, surgical results, 
perioperative, 30-day, and yearly outcomes of patients who 
underwent cardiac valve surgery for infective endocarditis
o Compare the resulting data for intravenous (IV) drug users 
versus non-IV drug users
o Evaluate the total hospital charges for the treatment of patients 
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o Average age of IV drug users is significantly lower than non-IV drug 
users (34.6 vs. 62.1)
o Bar graph shows IV drug users made up majority of patients with 
infection of the tricuspid valve, whereas non-IV drug users made up 
majority of patients with infections of the mitral and aortic valves
o Ventilator dependent respiratory failure (VDRF) and new need for a 
pacemaker implantation are the two most common complications 
researched in the IV-drug user group (22.2% and 33.3%)
o IV-drug user group had 20.0% mortality and non-IV drug user group 
had 17.7% mortality 
o Kaplan Meier analysis shows survival drop off for IV drug user group 
in the first 5 months and then a plateau, whereas non-users have a 
more gradual drop over the first 10 months before it plateaus 
o The median hospital charge for IV drug user patients is higher than 
non-IV drug users, but the data is less consistent in the IV drug user 
group
o There is a positive correlation between hospital LOS for patients and 
total hospital charges related to treatment of endocarditis 
o poor follow-up data from the IV drug user cohort makes it difficult to 
draw definite conclusions from the mortality data
o IV drug users are associated with a longer hospital LOS and higher 
total hospital charges
o Further research should include an increased sample size to help 
verify or reject trends in the data 
o the 1,227 other patients who did not undergo surgery could be 
reviewed to see how their post-antibiotic treatment mortalities and 
hospital charges compare 
Table 1. patient demographics and medical 
histories 
Table 2. displays patient perioperative and 
follow-up outcomes
Graph 1. number of IV drug user patients 
vs. non-IV drug user patients with IE for 
each valve
Graph 2. Kaplan Meier analysis showing the 
survival fraction over each full month; line a is 
non-IV drug users and b is IV-drug users
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n % n %
Age (years) 62.1±12.7 34.6±8.0
Female 18 31.6% 9 50.0%
COPD 5 8.8% 1 5.6%
CAD 16 28.1% 0 0.0%
Diabetes 23 40.4% 0 0.0%
Chronic Renal Disease 19 33.3% 2 11.1%
PVD 10 17.5% 1 5.6%
CVA 19 33.3% 1 5.6%
Prev. Dental Surgery 5 8.8% 2 11.1%
Prev. Myocardial Infarction 9 15.8% 1 5.6%
Prev. Open Heart Surgery 16 28.1% 1 5.6%
Non-IV Drug Users IV Drug Users 
n = 18n = 57
Operative n % n %
Hypertension 26 45.6% 2 11.1%
Redo Valve Replacement 15 26.3% 1 5.6%
Perioperative 
LOS (days) 19.9±10.8 33.9±20.0
Stroke 9 15.8% 0 0.0%
Renal Failure 7 12.3% 0 0.0%
VDRF 8 14.0% 4 22.2%
Atrial Fibrillation 11 19.3% 1 5.6%
Pacemaker 9 15.8% 6 33.3%
Ventricular Septal Defect 0 0.0% 0 0.0%
Postoperative
Reoperation 6 10.5% 2 11.1%
Readmission at 30 Days 19 33.3% 4 22.2%
No Follow up 6 10.5% 8 44.4%
Follow up (n) n = 51 n = 10
Mortality 9 17.7% 2 20.0%
In-House Mortality 2 3.9% 1 10.0%
30 Day Mortality 4 7.8% 0 0.0%
IV Drug Users 
n = 57 n = 18
Non-IV Drug Users 
Graph 3.  total hospital charges for the treatment 
of IE in patients from each group
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